
Co-payments unpacked: the real drivers behind member shortfalls
A practical guide to why co-payments arise, how schemes set them, and how advisers can help clients manage the risk.

A practical guide to why co-payments arise, how schemes set them, and how advisers can help clients manage the risk.

This edition of Cover to Cover explains medical scheme dependant rules, required documentation, and how advisers can help clients keep their families covered.

Medihelp says it will challenge the judgment while the cost of Elaprase awaits a final decision by the CMS Appeal Board.

This edition of Cover to Cover explains waiting periods, helping advisers guide clients on when benefits start and strategies to avoid gaps in cover.

New benefits, flexibility, and holistic well-being support strengthen Medihelp’s role as a healthcare partner, not just a funder.

The first edition of our new series unpacks the types of medical plan, who they suit, and why the cheapest option isn’t always the smartest choice.

Medihelp says its recovery plan is on track, with strong cost controls, younger members, and CMS-approved funding measures set to restore financial stability by 2026.

Three medical schemes fell below the 25% solvency threshold in 2023.

Downgrading to a lower plan may appear to be a cost-saving strategy, but it frequently results in increased out-of-pocket expenses.

Bestmed states pending rules for low-cost benefit options have further complicated efforts to reduce costs for members.

With major medical schemes reporting average contribution hikes exceeding 9%, members face tough choices in an increasingly unaffordable healthcare landscape.

The Council for Medical Schemes has advised medical schemes to limit their contribution increases for 2025 to 4.4% plus ‘reasonable’ utilisation estimates.

Medihelp submitted a CMS-approved three-year plan, requiring gradual contribution increases to restore its reserves to the statutory 25% level.

The expected legal challenges to the legislation and the pressure on the state’s finances could delay full implementation of the system for many years.

In 2022, the industry saw a net income of R2.57 billion – down from R12.18bn in 2021 – and faced an operating deficit of R6.155bn, the largest in 23 years.

The Council for Medical Schemes has withdrawn a directive for Discovery to retract its communication about contribution and benefit changes for 2024.

Discovery has lodged an appeal against a Council for Medical Schemes directive to retract communication to members about its 2024 contribution and benefit changes.